Lv4
530 积分 2022-04-27 加入
Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes
3天前
已完结
The present and future for CAR-T cell therapy in adult B-cell ALL
8天前
已完结
Aggressive Lymphoma after CD19 CAR T-Cell Therapy
1个月前
已完结
The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to control antitumor immunity
2个月前
已完结
Synergistic Integration of mRNA-LNP with CAR-Engineered Immune Cells: Pioneering Progress in Immunotherapy
3个月前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?
3个月前
已完结
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
3个月前
已完结
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients
4个月前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
5个月前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
6个月前
已完结
皖公网安备34019202002308
